Search
ABVC Biopharma Inc
ABVCAdd to Watchlist
1.800USD
+0.030+1.69%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
46.38MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.69%
5 Days
+17.65%
1 Month
+25.00%
6 Months
-17.81%
Year to Date
-15.49%
1 Year
-42.12%
Key Figures
1.780Open
1.836High
118.82KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.46%Turnover Ratio
1.770Prev. Close
1.690Low
141.46KTurnover
LossP/E Static
4.31P/B
0.00%Div Yield TTM
-52.72%ROA
5.48052wk High
1.01Volume Ratio
-4.90MNet Profit
25.77MShares
-0.3983EPS TTM
0.54Beta
-106.65%ROE
0.88052wk Low
8.25%Amplitude
100.00%Gross Margin
46.38MMarket Cap
3.89Reward/Risk
5.88%Risk Rate
TradingKey Stock Score of ABVC Biopharma Inc
Currency: USD Updated: 2026-07-02Key Insights
ABVC Biopharma Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 196 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ABVC Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
ABVC Biopharma Inc Highlights
StrengthsRisks
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
Fairly Valued
The company’s latest PE is -4.52, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 866.42K shares, decreasing 30.29% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
ABVC Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ABVC Biopharma Inc Info
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
Ticker SymbolABVC
CompanyABVC Biopharma Inc
CEOPatil (Uttam Yashwant)
Websitehttps://abvcpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of ABVC Biopharma Inc (ABVC)?
The current price of ABVC Biopharma Inc (ABVC) is 1.80.
What is the symbol of ABVC Biopharma Inc?
The ticker symbol of ABVC Biopharma Inc is ABVC.
What is the 52-week high of ABVC Biopharma Inc?
The 52-week high of ABVC Biopharma Inc is 5.48.
What is the 52-week low of ABVC Biopharma Inc?
The 52-week low of ABVC Biopharma Inc is 0.88.
What is the market capitalization of ABVC Biopharma Inc?
The market capitalization of ABVC Biopharma Inc is 46.38M.
What is the Earnings Per Share (EPS TTM) of ABVC Biopharma Inc (ABVC)?
The Earnings Per Share (EPS TTM) of ABVC Biopharma Inc (ABVC) is -0.39.